Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054661 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL30725970 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL2629461 | 0.91 | ALDH1A1 (0.55) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL30725971 | 0.91 | ALDH1A1 (0.55) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL30966448 | 0.91 | ALDH1A1 (0.55) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL29169330 | 0.90 | ALDH1A1 (0.63) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL15077679 | 0.89 | ALDH1A1 (0.47) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL15077681 | 0.89 | ALDH1A1 (0.47) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL5791797 | 0.85 | ALDH1A1 (0.47) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E | |
| SCHEMBL6324472 | 0.84 | ROR1 (0.51) | ALDH1A1ABCB1CYP3A4MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912577-B | Rockwell intermediate, rockwell and its derivative, and preparation and application | 深圳湾实验室 | 2023-12-29 | — | — | CN | disclosed |
| CN-113912577-A | Lockmilanol intermediate, Lockmilanol and derivatives thereof, preparation and application | 深圳湾实验室 | 2022-01-11 | — | — | CN | disclosed |
| CN-107473775-B | Method for recovering phosphorus and fluorine in phosphoric acid concentrated slag acid and co-producing low-fluorine water-soluble fertilizer | 中化云龙有限公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-107473775-A | Reclaim phosphorus and the molten fertile method of fluorine co-production low fluorine water in Phosphoric Acid Concentration slag acid | 中化化肥有限公司成都研发中心 | 2017-12-15 | — | — | CN | disclosed |
| US-9206100-B2 | Route to synthetic analogues of Rocaglamide and Aglafoline using cascade transformations initiated by oxy-cope rearrangement of bis-alkynes | The Florida State University Research Foundation, Inc. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20130165683-A1 | NEW ROUTE TO SYNTHETIC ANALOGUES OF ROCAGLAMIDE AND AGLAFOLINE USING CASCADE TRANSFORMATIONS INITIATED BY OXY-COPE REARRANGEMENT OF BIS-ALKYNES | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION INC. | 2013-06-27 | — | — | US | disclosed |
| WO-2012037062-A2 | NEW ROUTE TO SYNTHETIC ANALOGUES OF ROCAGLAMIDE AND AGLAFOLINE USING CASCADE TRANSFORMATIONS INITIATED BY OXY-COPE REARRANGEMENTS OF BIS-ALKYNES | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-6943182-B2 | Cyclopentabenzofuran derivatives and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-13 | — | — | US | disclosed |
| EP-0824524-B1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | UPJOHN CO (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| US-4822896-A | Method of synthesizing forskolin from 9-deoxyforskolin | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-04-18 | — | — | US | disclosed |
| US-4820826-A | CHEMICAL INTERMEDIATES | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-04-11 | — | — | US | disclosed |
| US-4808762-A | Insecticidal cyclopropyl-substituted di(aryl) compounds | FMC CORPORATION (US) | 1989-02-28 | — | — | US | disclosed |
| WO-1988008416-A1 | INSECTICIDAL CYCLOPROPYL-SUBSTITUTED DI(ARYL) COMPOUNDS | FMC CORPORATION (US) | 1988-11-03 | — | — | WO | disclosed |
| US-4734513-A | Method of synthesizing forskolin from 9-deoxyforskolin | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-03-29 | — | — | US | disclosed |
| EP-0243646-A1 | A process for the preparation of forskolin from 9-deoxy-forskolin and intermediates used therein | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4327070-A | Production of potassium formate from potassium sulfate | TRW INC. (US) | 1982-04-27 | — | — | US | disclosed |
| US-4254285-A | 1-Hydroxymethyl-1-1-oxo prostane derivatives of the E and F series | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
| US-4227011-A | 15-Deoxy-16-hydroxy-16-chloromethyl or bromomethyl prostaglandins of the E and F series | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-3970704-A | Alkoxy substituted aliphatic di-olefinic halides | ZOECON CORPORATION (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165683-A1 | NEW ROUTE TO SYNTHETIC ANALOGUES OF ROCAGLAMIDE AND AGLAFOLINE USING CASCADE TRANSFORMATIONS INITIATED BY OXY-COPE REARRANGEMENT OF BIS-ALKYNES | COASY, RIMKLA, ACSL3 | ALDH1A1 1262/4885ABCB1 1219/4885CYP3A4 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.